文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

利多卡因或曲马多预处理后辣椒素8%贴剂在周围神经病理性疼痛患者中的耐受性:一项多中心、随机、评估者盲法研究。

Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: a multicentre, randomized, assessor-blinded study.

作者信息

Jensen T S, Høye K, Fricová J, Vanelderen P, Ernault E, Siciliano T, Marques S

机构信息

Department of Neurology, Danish Pain Research Centre, Aarhus University Hospital, Denmark.

出版信息

Eur J Pain. 2014 Oct;18(9):1240-7. doi: 10.1002/j.1532-2149.2014.00479.x. Epub 2014 Mar 24.


DOI:10.1002/j.1532-2149.2014.00479.x
PMID:24664539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4232045/
Abstract

BACKGROUND: Application of the capsaicin 8% patch is associated with treatment-related discomfort. Consequently, pretreatment for 60 min with anaesthetic cream is recommended; however, this may be uncomfortable and time consuming. METHODS: We conducted a multicentre, randomized (1:1), assessor-blinded study in patients with peripheral neuropathic pain to assess tolerability of the capsaicin patch following topical lidocaine (4%) or oral tramadol (50 mg) pretreatment. The primary endpoint was the proportion of patients tolerating capsaicin patch application (ability to receive ≥90% of a 60-min application). Numeric Pain Rating Scale (NPRS) scores were assessed before, during and after treatment. RESULTS: Overall, 122 patients were included (61 per arm). The capsaicin patch was tolerated by 121 patients. Tolerability of the capsaicin patch was similar following pretreatment with lidocaine and tramadol. Following patch application, pain levels increased up to 55 min (change from baseline of 1.3 for lidocaine and 1.4 for tramadol). After patch removal, tramadol-treated patients experienced greater pain relief up to the end of day 1; in the evening, mean changes in NPRS scores from baseline were 0 for lidocaine and -1 for tramadol. Proportions of patients reporting increases of ≥2 NPRS points or >33% from baseline at one or more time point(s) on the day of treatment were similar between arms. Adverse event incidence was comparable between arms. CONCLUSIONS: Capsaicin 8% patch tolerability was similar in the two arms, with comparable results for most secondary endpoints. Tramadol given 30 min before patch application should be considered as an alternative pretreatment option in patients receiving capsaicin patch treatment.

摘要

背景:8%辣椒素贴剂的应用与治疗相关的不适有关。因此,建议使用麻醉乳膏预处理60分钟;然而,这可能会带来不适且耗时。 方法:我们对周围神经性疼痛患者进行了一项多中心、随机(1:1)、评估者盲法研究,以评估局部用利多卡因(4%)或口服曲马多(50毫克)预处理后辣椒素贴剂的耐受性。主要终点是能够耐受辣椒素贴剂应用的患者比例(能够接受60分钟应用的≥90%)。在治疗前、治疗期间和治疗后评估数字疼痛评分量表(NPRS)得分。 结果:总共纳入了122例患者(每组61例)。121例患者耐受了辣椒素贴剂。利多卡因和曲马多预处理后辣椒素贴剂的耐受性相似。贴剂应用后,疼痛水平在55分钟内升高(利多卡因组从基线变化1.3,曲马多组从基线变化1.4)。去除贴剂后,曲马多治疗的患者在第1天结束时疼痛缓解更明显;晚上,利多卡因组NPRS得分相对于基线的平均变化为0,曲马多组为-1。在治疗当天的一个或多个时间点报告NPRS得分较基线增加≥2分或>33%的患者比例在两组之间相似。两组不良事件发生率相当。 结论:两组中8%辣椒素贴剂的耐受性相似,大多数次要终点结果相当。在接受辣椒素贴剂治疗的患者中,贴剂应用前30分钟给予曲马多应被视为一种替代预处理选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/53ed749b9b34/ejp0018-1240-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/2c82e1b7354d/ejp0018-1240-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/bfc41c589686/ejp0018-1240-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/3a0b495b02b5/ejp0018-1240-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/ee6539ccd146/ejp0018-1240-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/53ed749b9b34/ejp0018-1240-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/2c82e1b7354d/ejp0018-1240-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/bfc41c589686/ejp0018-1240-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/3a0b495b02b5/ejp0018-1240-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/ee6539ccd146/ejp0018-1240-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30e8/4232045/53ed749b9b34/ejp0018-1240-f5.jpg

相似文献

[1]
Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: a multicentre, randomized, assessor-blinded study.

Eur J Pain. 2014-10

[2]
Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?

Pain Pract. 2013-12-1

[3]
Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study.

BMC Neurol. 2017-4-21

[4]
NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.

Lancet Neurol. 2008-12

[5]
[Effective pain relief of post-herpetic neuralgia with capsaicin patch].

Ugeskr Laeger. 2016-2-1

[6]
The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis.

Pain Med. 2013-5-24

[7]
Ipsilateral and contralateral sensory changes in healthy subjects after experimentally induced concomitant sensitization and hypoesthesia.

BMC Neurol. 2017-3-23

[8]
Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.

BMC Neurol. 2010-10-11

[9]
Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia.

BMC Anesthesiol. 2011-12-19

[10]
A randomized, prospective study of efficacy and safety of oral tramadol in the management of post-herpetic neuralgia in patients from north India.

Pain Pract. 2012-8-6

引用本文的文献

[1]
Is the Capsaicin 179 mg (8% w/w) Cutaneous Patch an Appropriate Treatment Option for Older Patients with Peripheral Neuropathic Pain?

J Pain Res. 2024-3-27

[2]
Neuropathic pain: Mechanisms and therapeutic strategies.

Front Cell Dev Biol. 2023-1-16

[3]
A systematic review of treatment for patients with burning mouth syndrome.

Cephalalgia. 2022-2

[4]
The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients.

J Diabetes Metab Disord. 2021-1-19

[5]
Comparative Study between Preemptive and Postoperative Intra-Articular Injection of Levobupivacaine and Tramadol for Control of Postoperative Pain.

Anesth Essays Res. 2019

[6]
The time course of brief and prolonged topical 8% capsaicin-induced desensitization in healthy volunteers evaluated by quantitative sensory testing and vasomotor imaging.

Exp Brain Res. 2018-8

[7]
Capsaicin, Nociception and Pain.

Molecules. 2016-6-18

[8]
Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland.

PLoS One. 2016-3-16

[9]
Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.

Drugs. 2016-1

本文引用的文献

[1]
Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch.

Br J Anaesth. 2011-8-17

[2]
Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia.

Expert Rev Neurother. 2011-1

[3]
A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.

Pain Med. 2010-11-18

[4]
Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain.

Drugs. 2010-10-1

[5]
The evidence for pharmacological treatment of neuropathic pain.

Pain. 2010-9

[6]
Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.

J Pain Symptom Manage. 2010-6

[7]
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.

Eur J Neurol. 2010-4-9

[8]
A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.

J Pain. 2010-4-18

[9]
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Mayo Clin Proc. 2010-3

[10]
NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.

Pain Med. 2010-1-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索